Scleroderma Biomarker Research Lands $11.3M NIH Funding
During the next five years, scleroderma researchers at four U.S. universities will use $11.3 million in funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health (NIH), to build up core services for conducting biomarker-focused research into systemic sclerosis (scleroderma). The goal of this massive research effort is to find biomarkers that can predict the onset of the disease and/or its major complications early enough to identify high-risk patients for possible participation in clinical trials and to aid in development of more targeted therapies.
The research effort will be led by the Boston University School of Medicine in Massachusetts and will include researchers at the University of Pittsburgh Medical Center in Pennsylvania; Northwestern University Feinberg School of Medicine in Chicago, Illinois; and Dartmouth Medical School in Hanover, New Hampshire. Read more...
Click here to read more news regarding scleroderma related research.
|Cure Crew's Gone Global!
Jaci Eisenberg is a graduate student currently studying in Switzerland. She can now also add 5K Runner and Fundraiser to her accomplishments! On December 3rd she ran her first 5K in Geneva in honor of her mom. We applaud Jaci for her successes; she completed the race in just under 32 minutes and raised nearly $4,000 for scleroderma research!
When Jaci made the commitment to do her first 5K she thought "what better way to celebrate it than to run it in honor of my mom and raise money for scleroderma research". We couldn't agree more and are deeply grateful for her commitment and inspiration! What do you want to celebrate today?
Jaci is an incredible example of how Cure Crew members are making a difference in the fight against scleroderma. Check out your local newspaper or visit Active.com to find an activity in your area, then click here to set up a personal Cure Crew page that will turn your participation into a difference for people with scleroderma!
|Early Detection of Scleroderma-Associated PAH Enhanced Survival
Early detection of incident systemic sclerosis-associated pulmonary arterial hypertension enhanced survival in a prospective cohort study of 131 patients from the multicenter PHAROS, according to data presented at the annual meeting of the American College of Rheumatology.
The survival rates for patients with incident systemic sclerosis (SSc)-associated pulmonary arterial hypertension who were enrolled in PHAROS (Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma) "were better than for other recently described cohorts, with 1- and 3-year survival of 93% and 75%, respectively," said principal investigator Dr. Lorinda Chung of the Department of Immunology and Rheumatology at Stanford (Calif.) University Medical Center. Read more...
Visit the Patient News section of our site for more articles to keep you informed.
Let Us Help With Your Holiday Gift Giving
This year, celebrate the season by honoring a special person in your life and supporting scleroderma research at the same time. Make a donation in honor or in memory of someone important to you - it's a gift they'll appreciate and one that can help so many.
With a gift of $25 or more, we'll send a special holiday card with your personal message to the recipient of your choice. Just (1) click the link below to make an online donation; (2) check the "in honor" box in the tribute section; (3) fill out the name and contact information for where you'd like us to send your card; and (4) write your personal note in the comments field at the bottom (we'll know it's for the holidays). Send your holiday card today by clicking here. Or, call us at 1-800-441-CURE from 9 AM to 5 PM PST Monday through Friday.
Thank you for being a part of our family and for helping us to fund the research that will make life better for people everywhere living with scleroderma.
Wishing you all the best this holiday season,
Scleroderma Research Foundation
Make a Donation 1-800-441-CURE (2873)